Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren, ramipril, and aliskiren + amlodipine in elderly patients with essential hypertension
2013-001562-42Phase 4Terminated
- Sponsor
- Novartis
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of aliskiren and amlodipine in essential hypertension (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline to Week 8 in mean sitting systolic blood pressure. Started Nov 2013; status: terminated.
02
Drugs
aliskirenamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2013-001562-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001562-42.